These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 35408946)

  • 1. Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus.
    Nakamura K; Miyoshi T; Yoshida M; Akagi S; Saito Y; Ejiri K; Matsuo N; Ichikawa K; Iwasaki K; Naito T; Namba Y; Yoshida M; Sugiyama H; Ito H
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetic Cardiomyopathy: From Mechanism to Management in a Nutshell.
    Khan S; Ahmad SS; Kamal MA
    Endocr Metab Immune Disord Drug Targets; 2021; 21(2):268-281. PubMed ID: 32735531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy.
    Ritchie RH; Zerenturk EJ; Prakoso D; Calkin AC
    J Mol Endocrinol; 2017 May; 58(4):R225-R240. PubMed ID: 28373293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial Dysfunction and Diabetic Cardiomyopathy.
    Wang M; Li Y; Li S; Lv J
    Front Endocrinol (Lausanne); 2022; 13():851941. PubMed ID: 35464057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants.
    Prandi FR; Evangelista I; Sergi D; Palazzuoli A; Romeo F
    Heart Fail Rev; 2023 May; 28(3):597-606. PubMed ID: 35001338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiomyopathy in obesity, insulin resistance and diabetes.
    Nakamura M; Sadoshima J
    J Physiol; 2020 Jul; 598(14):2977-2993. PubMed ID: 30869158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic cardiomyopathy and inflammation: development of hostile microenvironment resulting in cardiac damage.
    Elia E; Ministrini S; Carbone F; Montecucco F
    Minerva Cardiol Angiol; 2022 Jun; 70(3):357-369. PubMed ID: 33427423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic cardiomyopathy: a brief summary on lipid toxicity.
    Ke J; Pan J; Lin H; Gu J
    ESC Heart Fail; 2023 Apr; 10(2):776-790. PubMed ID: 36369594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exercise Amaliorates Metabolic Disturbances and Oxidative Stress in Diabetic Cardiomyopathy: Possible Underlying Mechanisms.
    Mahmoud AM
    Adv Exp Med Biol; 2017; 999():207-230. PubMed ID: 29022265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Cardiac Fibrosis in Diabetic Cardiomyopathy: From Pathophysiology to Clinical Diagnostic Tools.
    Pan KL; Hsu YC; Chang ST; Chung CM; Lin CL
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial dysfunction in diabetic cardiomyopathy.
    Duncan JG
    Biochim Biophys Acta; 2011 Jul; 1813(7):1351-9. PubMed ID: 21256163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.
    Jia G; Hill MA; Sowers JR
    Circ Res; 2018 Feb; 122(4):624-638. PubMed ID: 29449364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetic cardiomyopathy--fact or fiction?
    Maisch B; Alter P; Pankuweit S
    Herz; 2011 Mar; 36(2):102-15. PubMed ID: 21424347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SIRT6: A potential therapeutic target for diabetic cardiomyopathy.
    Wu T; Qu Y; Xu S; Wang Y; Liu X; Ma D
    FASEB J; 2023 Aug; 37(8):e23099. PubMed ID: 37462453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
    Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
    Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy.
    Alonso N; Moliner P; Mauricio D
    Adv Exp Med Biol; 2018; 1067():197-217. PubMed ID: 28980272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of cardiac pathology in diabetes - Experimental insights.
    Varma U; Koutsifeli P; Benson VL; Mellor KM; Delbridge LMD
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt B):1949-1959. PubMed ID: 29109032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms.
    Huang K; Luo X; Liao B; Li G; Feng J
    Cardiovasc Diabetol; 2023 Apr; 22(1):86. PubMed ID: 37055837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of hyperglycaemia in the development of diabetic cardiomyopathy.
    El Hayek MS; Ernande L; Benitah JP; Gomez AM; Pereira L
    Arch Cardiovasc Dis; 2021 Nov; 114(11):748-760. PubMed ID: 34627704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.
    Palomer X; Salvadó L; Barroso E; Vázquez-Carrera M
    Int J Cardiol; 2013 Oct; 168(4):3160-72. PubMed ID: 23932046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.